Sylvamo Posts $1.33 Third-Quarter Non-GAAP EPS, Beating Estimate by 20 Cents

Sylvamo Corporation reported Q3 non-GAAP EPS of $1.33, surpassing estimates by $0.20, with revenue at $645 million, down 2.6% YoY. The company's earnings exceeded expectations despite a revenue decline.

Original reporting
Published Nov 8, 2026, 6:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sylvamo Posts $1.33 Third-Quarter Non-GAAP EPS, Beating Estimate by 20 Cents — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings beat provides a fresh catalyst that could trigger short‑term buying pressure.

02

Market read

First‑report earnings beat for a small‑cap; modest but actionable for short‑term traders.

03

What to watch

Margin pressure from cost inflation may limit upside despite the beat.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Sylvamo is a U.S. paper and packaging company listed on NYSE under SYMM.

Market effects

Paper and packaging sector may see modest uplift from a peer beat.

U.S. small‑cap market could see a slight positive bias.

Limited; impact confined to U.S. equities.

Counterpoint

Revenue decline could signal weakening demand, offsetting the EPS beat.

Key entities

  • Sylvamo Corporation

    U.S. paper and packaging manufacturer.

Related articles

$SLVMMedAI 8/10

Sylvamo Q3 Earnings Call Highlights

Sylvamo (SLVM) reported Q3 adjusted EBITDA improved by $25M due to price increases, with flat volume. Input costs rose by $6M, but the company expects to mitigate further increases. Projects at Eastover and Sumter mills are on track, with expected capacity expansions. The company declined to update free cash flow targets post-Europe transaction but reaffirmed capital allocation priorities, including dividends and share repurchases.

$SLVMMed

Sylvamo Corp (SLVM) (Q3 2026) Earnings Call Highlights: Adjusted EBITDA Nearly Doubles

Sylvamo Corp (SLVM) reported Q3 2026 adjusted EBITDA of $128M, nearly doubling from Q2. CEO John Sims and CFO John Devlin discussed 2027 outlook, noting uncertainties but expecting $25M of non-repeat items. They also addressed the Europe deal, Sumter sheeter expansion, and cost mitigation strategies. The company's shareholder rights plan will expire on Nov 9, 2026. North America shipments are expected to be flat in 2027, with industry decline of about 2% in 2026.

Med

Sylvamo Corporation Q3 2026 Earnings Call Summary

Sylvamo Corporation reported Q3 2026 earnings, highlighting a strategic pivot to North and Latin America, operational improvements, and planned divestiture of European business by Q1 2027. The company expects $6M higher input costs in Q4 2026 and projects flat North American volume in 2027. Management deferred new free cash flow targets until the European sale is finalized, prioritizing balance sheet strength and high-return projects.

$SLVMMed

Sylvamo (SLVM) Q3 2026 Earnings Call Transcript

Sylvamo (SLVM) reported Q3 2026 net sales of $645 million, adjusted EBITDA of $128 million, and adjusted earnings of $1.33 per share. The company agreed to divest European operations, retaining a 20% interest, and plans capacity expansions in the U.S. Management highlighted price increases and operational improvements but noted ongoing cost pressures. The board did not renew the shareholder rights plan. (350 characters)

$SLVMMed

Sylvamo Reports Third Quarter 2026 Earnings

Sylvamo (SLVM) reported Q3 2026 earnings, with net sales of $645M from continuing operations and net income of $85M ($2.13 per share). The company announced a potential sale of its Europe business to Midas Atlantic Partners and The Najafi Companies. Sylvamo declared a $0.45 per share dividend and is investing in strategic projects at its Eastover mill. The company expects to focus on Latin America and North America post-transaction.

$SLVMMed

Sylvamo 3Q 2026: Revenue $645M, EPS ($4.98) — 10-Q Summary

Sylvamo reported 3Q 2026 revenue of $645M, down 2.6% YoY, and a net loss of $199M, a 449.1% decline. Lower volume from the Riverdale mill agreement termination impacted sales, while higher costs pressured profits. A Europe-segment impairment drove the net loss. Capital spending was $156M for the first nine months of 2026.